Zoledronic Acid: 4 agencies, 2001–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 21.7 years separate the first record, 1 Nov 2001 at PHARMAC (New Zealand), from the most recent, 2023 at PBAC (Australia).
SMC (Scotland) changed its position: not recommended on 12 Jan 2004, restricted by 10 Mar 2008, after a resubmission.
No assessment is on file from HAS (France), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for zoledronic acid, 1 submission was never made — an outcome set by the company rather than the assessor.
5 distinct indication wordings are recorded for zoledronic acid by the agencies that label one in English (PBAC and SMC).
1 of these 16 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess zoledronic acid, on 1 Nov 2001; PBAC (Australia) did not open a file until 2023 — an unusually long tail of 21.7 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 13 years in total.
3 of the 4 agencies here assessed zoledronic acid more than once, PHARMAC (New Zealand) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed zoledronic acid.
The full ledger for zoledronic acid reads 11 recommended, 2 not recommended, 1 non-submission and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Adjuvant treatment of breast cancer | Recommended | source |
| PHARMAC (New Zealand) | 6 Aug 2021 | Moderate to severe hypercalcaemia | PTAC advice: High · decision reached | source |
| TLV (Sweden) | 16 Dec 2011 | Ny form av Zometa ingår i högkostnadsskyddet | general subsidy | source |
| SMC (Scotland) | 12 Jan 2009 | Treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture. | not recommended | source |
| PHARMAC (New Zealand) | 3 Aug 2003 | Bone metastases associated with prostate cancer, breast cancer and multiple myeloma | PTAC advice: Decline · decision reached | source |
11 further decisions for zoledronic acid, across 3 agencies, are not shown here. They link to 11 further source documents.
Related molecules
- denosumab — same ATC class M05B — Bone diseases
- burosumab — same ATC class M05B — Bone diseases
- romosozumab — same ATC class M05B — Bone diseases
- vosoritide — same ATC class M05B — Bone diseases
- dibotermin alfa — same ATC class M05B — Bone diseases
- ibandronic acid — same ATC class M05B — Bone diseases
Coverage: 16 decisions for zoledronic acid from 4 agencies, 2001 to 2023. Data to 7 Sep 2026. ATC class M05B — Bone diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.